NovoBay supports diagnostics and pharmaceutical companies with market expansion and access, clinical collaboration, companion diagnostics, channel development and business partnerships.
Based in Hong Kong, we connect Mainland Greater Bay Area cities with global resources and turn opportunities into actionable projects.
NovoBay is not defined by a single technology platform. We focus on the cross-regional growth needs of diagnostics and pharmaceutical companies, organizing market assessment, clinical collaboration, partner development and commercialization into clear pathways.
Starting with the business goals of diagnostics and pharmaceutical companies, NovoBay assesses market opportunities and routes forward, connects clinical, industry and commercial resources, and advances early opportunities into clearly scoped, actionable projects.
Assess market opportunities, key stakeholders and phased pathways based on product attributes, evidence status, target markets and commercial goals.
Connect suitable hospitals, experts and research teams to assess research questions, collaboration conditions, validation resources and project-launch arrangements.
Connect pharmaceutical companies, diagnostics providers and specialist resources around biomarker, patient-stratification and testing needs to shape collaborative solutions.
Map the channel ecosystem, identify prospective business partners and advance discussions with priority institutions according to product stage and target market.
Resources alone are not outcomes. NovoBay screens partners, organizes specialist capabilities and coordinates project pace around enterprise goals, enabling networks across Mainland China and global markets, connected through Hong Kong, to serve defined commercialization objectives.
Strategic assessment · Partner screening
Resource coordination · Milestone advancement
Identify priority opportunities and constraints in target markets based on product stage, evidence conditions and enterprise goals.
Connect and screen suitable hospitals, experts, CROs, channels and industry partners to form project-specific resource combinations.
Build alignment on scope, responsibilities and key milestones so collaboration can move from discussion into execution.
Hong Kong is both NovoBay's base and current priority market, as well as an important gateway connecting Mainland China and global partnerships. We assess priority routes for two-way market expansion according to each company's direction and project stage.
Help multinational diagnostics and pharmaceutical companies understand the market, clinical and partnership ecosystems in Hong Kong and Mainland Greater Bay Area cities, and assess phased routes forward.
Connect Hong Kong's international professional services, clinical research and industry networks to help Mainland Chinese companies assess overseas partnership opportunities and implementation requirements.
Coordinate clinical, manufacturing, supply-chain and channel resources around specific projects to advance cross-regional collaboration.
The following are selected partner products and technology platforms currently connected through NovoBay. The network will continue to expand in response to diagnostics, clinical research and drug-development needs; specific capabilities are provided by the relevant partners.
Product and technology source: KDX Biotech. Registration status and intended use of Q-VELOX Q100 are subject to official product materials and applicable local requirements.
Platform and technology source: Polyseq Biotech. Specific performance and intended applications are subject to the partner's formal technical materials.
NovoBay Biotechnology Company Limited was formally established in Hong Kong and began building a collaborative network connecting diagnostics and pharmaceutical companies with clinical, research and commercial partners.
